LifeSci Capital Issues Equity Research Report on Addex Therapeutics
Geneva, Switzerland, 20 July 2016 – Addex Therapeutics (SIX: ADXN), announced today that the independent life science research firm, LifeSci Capital has issued an equity research report on Addex Therapeutics. The research report highlights the significant potential of Addex portfolio of drug candidates and in particular dipraglurant for Parkinson’s disease levodopa-induced dyskinesia.
PD-LID is the most important unmet medical need after a disease-modifying agent for Parkinson’s disease. Dipraglurant was awarded orphan drug designation by the US FDA earlier this year and recently completed a receptor occupancy study in collaboration with the Johns Hopkins University and funding from The Michael J. Fox Foundation for Parkinson’s Research. LifeSci estimates the US sales of dipraglurant in PD-LID could be as high as US$1.6 billion with a 50% market penetration.
“This equity research report from US based LifeSci Capital provides a useful in depth analysis of the Addex investment case,” commented Tim Dyer, CEO of Addex. “With dipraglurant ready to start Phase III in PD-LID and scheduled to start a Phase II POC in focal cervical dystonia, the Addex turnaround is well on track to deliver significant value to our shareholders.”
ADX71441, a second Addex drug candidate, recently demonstrated positive results in a non-human primate model of cocaine addiction. This data together with data already generated in nicotine and alcohol use disorder models, shows the broad potential of ADX71441 in these major public health needs.
The full analyst research report is available on www.lifescicapital.com and on Addex website at www.addextherapeutics.com under Investors/downloads/analyst reports.
About LifeSci Capital
LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. The firm’s service model as a boutique investment bank is unique in that LifeSci exclusively serves emerging life science companies that discover, develop, and commercialize innovative products. LifeSci views its clients as partners, and the firm works closely with them to establish and execute their capital markets strategies. LifeSci’s broadly-distributed equity research product is differentiated and provides a deep understanding of its clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the firm’s website, www.lifescicapital.com.
About Addex Therapeutics
Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a phase IIa POC in Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter phase III for PD-LID with support from the Michael J. Fox Foundation for Parkinson’s Research (MJFF). In parallel, dipraglurant’s therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start phase I and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), alcohol use disorder, cocaine and nicotine dependence. Discovery programs include mGluR4PAM for neurodegenerative diseases, mGluR7NAM for psychosomatic disorders and TrkBPAM for neurodegenerative disorders which are being advanced in collaboration with the Universities of Lausanne and Geneva under the Swiss CTI grant program; and mGluR3PAM which is being advanced in collaboration with Pierre Fabre Pharmaceuticals. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.
Chief Executive Officer
Telephone: +41 22 884 15 61
Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.